Artificial nucleic acid molecules
AssigneeCureVac AG
InventorsStefanie Grund, Thomas Schlake
Life of this patent
Estimating the term…
Abstract
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence which is derived from the 3′-UTR of a FIG4 gene or from a variant of the 3′-UTR of a FIG4 gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a FIG4 gene or from a variant of the 3′-UTR of a FIG4 gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3′-UTR element.
Claims22
An artificial nucleic acid molecule comprising
- a) at least one open reading frame (ORF) encoding a pathogen antigen, tumor antigen or a human therapeutic protein,
- b) at least one Sac Domain-Containing Inositol Phosphatase 3 (FIG4) 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence from a human FIG4 gene 3′-UTR, and
- c) a poly(A) sequence having a length of 40 to 200 adenine nucleotides,
- wherein said ORF is heterologous to said 3′-UTR element and wherein said 3′-UTR element is positioned between said ORF and said poly(A) sequence.
A vector comprising
- a) an open reading frame encoding a pathogen antigen, tumor antigen or a human therapeutic protein,
- b) at least one Sac Domain-Containing Inositol Phosphatase 3 (FIG4) 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence from a human FIG4 gene 3′-UTR, and
- c) a poly(A) sequence having a length of 40 to 200 adenine nucleotides,
- wherein said ORF is heterologous to said 3′-UTR element and wherein said 3′-UTR element is positioned between said ORF and said poly(A) sequence.
A purified artificial mRNA molecule comprising, from 5′ to 3′,
- a) at least one open reading frame (ORF) encoding a pathogen antigen, tumor antigen or a human therapeutic protein,
- b) at least one Sac Domain-Containing Inositol Phosphatase 3 (FIG4) 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence from a human FIG4 gene 3′-UTR, and
- c) a poly(A) sequence having a length of 40 to 200 adenine nucleotides,
- wherein said ORF is heterologous to said 3′-UTR element.
Dependencies are inferred from the claim text.